US2003129703A1PendingUtilityA1

Modified dorsal tissue affecting factor and compositions

51
Priority: Jul 17, 1997Filed: Dec 19, 2002Published: Jul 10, 2003
Est. expiryJul 17, 2017(expired)· nominal 20-yr term from priority
Inventors:Aris N. EconomidesNeil StahlRichard M. Harland
A61P 19/08A61K 38/00C07K 14/475
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described are modified Noggin muteins, compositions comprising the muteins, and DNA or RNA sequences comprising coding (sense) or antisense sequences for the muteins.

Claims

exact text as granted — not AI-modified
1 . Human Noggin modified by a deletion of amino acid residues 138-144.  
     
     
         2 . An isolated nucleic acid molecule encoding the modified human Noggin of  claim 1 .  
     
     
         3 . An isolated nucleic acid molecule of  claim 2 , which is a recombinant DNA molecule operatively linked to an expression control sequence.  
     
     
         4 . A host cell transformed with the recombinant DNA molecule of  claim 3 .  
     
     
         5 . A method for producing a modified Noggin molecule comprising: 
 (a) growing a recombinant host cell containing the DNA molecule of  claim 3 , so that the DNA molecule is expressed by the host cell to produce the modified Noggin molecule and (b) isolating the expressed, modified Noggin molecule.    
     
     
         6 . The method according to  claim 5 , wherein said host cell is a eukaryotic cell.  
     
     
         7 . The method according to  claim 5 , wherein said host cell is a prokaryotic cell.  
     
     
         8 . A composition comprising human Noggin according to  claim 1 , and a pharmaceutical carrier.  
     
     
         9 . A method of treatment comprising administering to a patient an effective amount of the composition of  claim 8 .  
     
     
         10 . Human Noggin modified by a deletion of amino acid residues 133-144.  
     
     
         11 . An isolated nucleic acid molecule encoding the modified human Noggin of  claim 10 .  
     
     
         12 . An isolated nucleic acid molecule of  claim 11 , which is a recombinant DNA molecule operatively linked to an expression control sequence.  
     
     
         13 . A host cell transformed with the recombinant DNA molecule of  claim 12 .  
     
     
         14 . A method for producing a modified Noggin molecule comprising: 
 (a) growing a recombinant host cell containing the DNA molecule of  claim 12 , so that the DNA molecule is expressed by the host cell to produce the modified Noggin molecule and (b) isolating the expressed, modified Noggin molecule.    
     
     
         15 . The method according to  claim 14 , wherein said host cell is a eukaryotic cell.  
     
     
         16 . The method according to  claim 14 , wherein said host cell is a prokaryotic cell.  
     
     
         17 . A composition comprising human Noggin according to  claim 2  and a pharmaceutical carrier.  
     
     
         18 . A method of treatment comprising administering to a patient an effective amount of the composition of  claim 17 .  
     
     
         19 . Biologically active noggin polypeptide modified by the deletion of the amino acid sequence KKLRRK.  
     
     
         20 . A nucleic acid molecule that encodes the noggin polypeptide of  claim 19.

Join the waitlist — get patent alerts

Track US2003129703A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.